Literature DB >> 27569861

5-Bromo-2-hydroxy-4-methyl-benzaldehyde inhibited LPS-induced production of pro-inflammatory mediators through the inactivation of ERK, p38, and NF-κB pathways in RAW 264.7 macrophages.

Kil-Nam Kim1, Seok-Chun Ko2, Bo-Ram Ye3, Min-Sun Kim3, Junseong Kim3, Eun-Yi Ko4, Su-Hyeon Cho4, Daekyung Kim1, Soo-Jin Heo5, Won-Kyo Jung6.   

Abstract

The aim of the present study was to investigate the effects of 5-bromo-2-hydroxy-4-methyl-benzaldehyde (BHMB) on inflammatory responses to lipopolysaccharide (LPS) in RAW 264.7 cells and the associated mechanism of action. BHMB concentration-dependently suppressed protein and mRNA expressions of iNOS and COX-2, thereby inhibiting the production of NO and PGE2 in LPS-stimulated RAW 264.7 cells. BHMB also reduced the mRNA expression of TNF-α, IL-6, and IL-1β in LPS-stimulated RAW 264.7 cells. To elucidate the mechanism underlying the anti-inflammatory activity of BHMB, we investigated the effects of BHMB on the mitogen-activated protein kinase and nuclear factor-kappa B (NF-κB) pathways. BHMB suppressed the phosphorylation and degradation of IκB-α and markedly inhibited the nuclear translocation of p65 and p50 in LPS-stimulated RAW 264.7 cells. The compound also inhibited the LPS-stimulated phosphorylation of ERK and p38. Taken together, these results illustrated that BHMB suppresses pro-inflammatory mediator and cytokine expression in LPS-stimulated RAW 264.7 cells by inhibiting the phosphorylation of ERK and p38 and the activation of NF-κB.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  5-Bromo-2-hydroxy-4-methyl-benzaldehyde (BHMB); MAPKs; NF-κB; Proinflammatory; RAW 264.7 cells

Mesh:

Substances:

Year:  2016        PMID: 27569861     DOI: 10.1016/j.cbi.2016.08.022

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  7 in total

1.  Anti-Inflammatory Effect of Turbo cornutus Viscera Ethanolic Extract against Lipopolysaccharide-Stimulated Inflammatory Response via the Regulation of the JNK/NF-kB Signaling Pathway in Murine Macrophage RAW 264.7 Cells and a Zebrafish Model: A Preliminary Study.

Authors:  Eun-A Kim; Nalae Kang; Junseong Kim; Hye-Won Yang; Ginnae Ahn; Soo-Jin Heo
Journal:  Foods       Date:  2022-01-27

2.  In Silico Virtual Screening of Marine Aldehyde Derivatives from Seaweeds against SARS-CoV-2.

Authors:  Nalae Kang; Seong-Yeong Heo; Seon-Heui Cha; Ginnae Ahn; Soo-Jin Heo
Journal:  Mar Drugs       Date:  2022-06-16       Impact factor: 6.085

3.  NF-κB pathways are involved in M1 polarization of RAW 264.7 macrophage by polyporus polysaccharide in the tumor microenvironment.

Authors:  Chun-Ping Liu; Xian Zhang; Qing-Long Tan; Wen-Xing Xu; Chang-Yuan Zhou; Min Luo; Xiong Li; Run-Yue Huang; Xing Zeng
Journal:  PLoS One       Date:  2017-11-20       Impact factor: 3.240

4.  Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode.

Authors:  Spiros A Vlahopoulos
Journal:  Cancer Biol Med       Date:  2017-08       Impact factor: 4.248

5.  The protective effects of PCPA against monocrotaline-induced pulmonary arterial hypertension are mediated through the downregulation of NFAT-1 and NF-κB.

Authors:  Yang Bai; Zhong-Xia Li; Huai-Liang Wang; Guo-Chao Lian; Yun Wang
Journal:  Int J Mol Med       Date:  2017-05-26       Impact factor: 4.101

6.  Angiotensin II induces RAW264.7 macrophage polarization to the M1‑type through the connexin 43/NF‑κB pathway.

Authors:  Lei Wu; Kai Chen; Jingjie Xiao; Junzhou Xin; Liang Zhang; Xinzhi Li; Li Li; Junqiang Si; Li Wang; Ketao Ma
Journal:  Mol Med Rep       Date:  2020-03-12       Impact factor: 2.952

7.  NLRP1-Mediated Antidepressant Effect of Ketamine in Chronic Unpredictable Mild Stress Model in Rats.

Authors:  Feyza Aricioğlu; Canan Yalcinkaya; Ceren Sahin Ozkartal; Erdem Tuzun; Serap Sirvanci; Cem Ismail Kucukali; Tijen Utkan
Journal:  Psychiatry Investig       Date:  2020-03-24       Impact factor: 2.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.